CLINICAL TRIALS PROFILE FOR METAXALONE
✉ Email this page to a colleague
All Clinical Trials for METAXALONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03068897 ↗ | Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain | Completed | Montefiore Medical Center | Phase 4 | 2017-05-03 | This is a randomized study, based in emergency departments, in which the investigators determine the utility of adding various skeletal muscle relaxants to standard therapy, which consists of ibuprofen and an educational session. Patients will be enrolled at the time of an emergency visit and followed for three months to determine outcomes. |
| NCT04003350 ↗ | The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty | Completed | Rothman Institute Orthopaedics | N/A | 2017-12-21 | It is well recognized that a multimodal analgesia program targeting multiple pain pathways, is more effective for controlling pain during the hospital stay and in the acute postoperative period than monotherapy-based regimens, such as opioids only. This multimodal analgesic regimen also leads to reduce opioid consumption and its related side effects after hip and knee joint replacement procedures. One potential strategy to reduce the use of opioids after TKA is to administer a prolonged oral multimodal pain regimen that targets multiple pain pathways in the post hospital discharge period. This can be equal or more effective than the regimen of opioid prescriptions used after TKA. To the best of our knowledge, there have been no studies conducted that directly examine the effect of prolonged multimodal pain regimen after hospital discharge in primary TKA patients. PURPOSE: 1. To determine whether a prolonged multimodal pain regimen after discharge from primary TKA can provide equivalent or better pain control while reducing opioid consumption and, subsequently, opioid-related side effects. 2. To determine whether patient expectations and routine opioid prescription practices at the time of discharge from primary TKA impacts opioid consumption. |
| NCT06157177 ↗ | Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. | Recruiting | Illumination Health | Phase 4 | 2023-11-15 | The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: - Amount and quality of pain - Interference with physical activity - Interference with sleep |
| NCT06157177 ↗ | Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. | Recruiting | Primus Pharmaceuticals | Phase 4 | 2023-11-15 | The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: - Amount and quality of pain - Interference with physical activity - Interference with sleep |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METAXALONE
Condition Name
Clinical Trial Locations for METAXALONE
Trials by Country
Clinical Trial Progress for METAXALONE
Clinical Trial Phase
Clinical Trial Sponsors for METAXALONE
Sponsor Name
